Stock ATXS ASTRIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 02:44:38 2024-04-23 pm EDT 		5-day change 1st Jan Change
9.755 USD -0.46% Intraday chart for Astria Therapeutics, Inc. -11.71% +27.60%
02:01pm HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating MT
Apr. 09 Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Astria Therapeutics, Inc.

HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating MT
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee CI
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating MT
Transcript : Astria Therapeutics, Inc. - Special Call
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE CI
North American Morning Briefing : Markets on Hold -2- DJ
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index CI
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Astria Therapeutics Shares Rise After Pricing of $125 Million Underwritten Offering MT
Astria Therapeutics Files $500 Million Mixed Shelf MT
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating MT
Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating MT
Transcript : Astria Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms DJ
Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting CI
Wedbush Adjusts Price Target on Astria Therapeutics to $18 From $25, Maintains Outperform Rating MT
Transcript : Astria Therapeutics, Inc. - Special Call
HC Wainwright Adjusts Astria Therapeutics Price Target to $18 From $20, Maintains Buy Rating MT
Indian Equities End Lower on Profit Booking; IT Tops Laggards MT
Astria Therapeutics Prices Common Stock, Warrants Offering for Expected Gross Proceeds of About $64 Million MT
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics MT
Ichnos Sciences Enters Licensing Agreement for Ox40 Antibody Portfolio with Astria Therapeutics CI

Chart Astria Therapeutics, Inc.

Chart Astria Therapeutics, Inc.
More charts

Company Profile

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Sector
Biotechnology & Medical Research
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.8 USD
Average target price
25.29 USD
Spread / Average Target
+158.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASTRIA THERAPEUTICS, INC. Stock Astria Therapeutics, Inc.
+27.60% 538M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.42% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.51% 96.73B
ARGENX SE Stock argenx SE
+1.66% 21.31B
BIONTECH SE Stock BioNTech SE
-16.13% 21.21B
GENMAB A/S Stock Genmab A/S
-6.82% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-23.05% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.39% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+23.07% 10.98B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATXS Stock
  4. News Astria Therapeutics, Inc.
  5. Catabasis Pharmaceuticals : Wedbush Downgrades Catabasis Pharmaceuticals to Neutral From Outperform, Adjusts PT to $1.15 From $15 on Edasalonexent/DMD Discontinuation